Medacta Reports Above-Market Revenue Growth of 9.7% in H1 2026

Medacta Group SA reported continued above-market revenue growth of 9.7% in constant currency during the first half of 2026, exceeding the record high comparable base from last year.

The company's revenue reached Euro 368 million for the period ending June 30, 2026, with a growth rate of 7.0% in Euro.

Francesco Siccardi, CEO of Medacta, stated that the company delivered another semester of above-market growth due to its unique position and business model, which focuses on differentiating innovations and surgeon-specific medical education to improve patient outcomes.

The good growth was achieved across all business lines and geographies, driven by continued differentiating innovations, the successful attraction of new surgeons supported through Medacta's expanded sales force, and sustained focus on medical education.